Gandolfi O, Barbaccia M L, Chuang D M, Costa E
Neuropharmacology. 1983 Jul;22(7):927-9. doi: 10.1016/0028-3908(83)90143-0.
In rats receiving daily doses (50 mg/kg i.p. twice daily) of bupropion HCI (WellbutrinR) repeated for 21 days the Bmax of the beta-adrenergic receptor recognition sites located in the frontal cortex is reduced. This decrease is not associated with a decrease of the apparent affinity of these recognition sites. However the Vmax of the cAMP (cyclic AMP) generating system stimulated by NE is reduced suggesting that similarly to other antidepressants bupropion down regulates beta-adrenergic receptors located in the frontal cortex. Bupropion neither inhibits MAO (monoamine oxidase) nor releases biogenic amines but only weakly inhibits monoamine uptake in vitro.
在每日给予盐酸安非他酮(维思通)剂量(50毫克/千克,腹腔注射,每日两次)并持续21天的大鼠中,位于额叶皮质的β-肾上腺素能受体识别位点的Bmax降低。这种降低与这些识别位点的表观亲和力降低无关。然而,由去甲肾上腺素刺激的环磷酸腺苷(cAMP)生成系统的Vmax降低,这表明与其他抗抑郁药类似,安非他酮下调位于额叶皮质的β-肾上腺素能受体。安非他酮既不抑制单胺氧化酶(MAO),也不释放生物胺,仅在体外微弱抑制单胺摄取。